Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Advanced Solid Tumors 5Carcinoma, Non-Small-Cell Lung 3Solid Tumors 2Rectal Neoplasms 2Colonic Neoplasms 2Solid Tumor 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Advanced or Metastatic Solid Tumors 1Adenocarcinoma 1

Interventions

Irinotecan 6Gemcitabine 5130-nm albumin-bound paclitaxel 5Oxaliplatin 4Fluorouracil 4Capecitabine 4Bevacizumab 4Albumin-Bound Paclitaxel 4napabucasin 3Ocoxin 3Leucovorin 3pembrolizumab 2Sorafenib 2Paclitaxel 2Nivolumab 2Drug Therapy 2Cyclophosphamide 2Colonoscopy 2Cetuximab 2Bupivacaine 2Aspirin 2Ascorbic Acid 2trifluridine tipiracil drug combination 1trametinib 1pralsetinib 1penpulimab 1ozanimod 1lutetium Lu 177 dotatate 1linifanib 1hetrombopag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Digestive System Diseases × linifanib × Clear all
NCT01009593 2012-09-10

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Abbott

Phase 3 Terminated
1,035 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡